|
1
|
Cabre A, Babio N, Lazaro I, Lázaro I,
Bulló M, Garcia-Arellano A, Masana L and Salas-Salvadó J: FABP4
predicts atherogenic dyslipidemia development. The PREDIMED study.
Atherosclerosis. 222:229–234. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tawada A, Kanda T, Imazeki F and Yokosuka
O: Prevention of Hepatitis B virus-associated liver diseases by
antiviral therapy. Hepatol Int. 10:574–593. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
de Franchis R, Hadengue A, Lau G, Lavanchy
D, Lok A, McIntyre N, Mele A, Paumgartner G, Pietrangelo A, Rodés
J, et al: EASL international consensus conference on Hepatitis B.
13–14 September, 2002 Geneva, Switzerland. Consensus statement
(long version). J Hepatol. 39 (Suppl 1):S3–S25. 2003.PubMed/NCBI
|
|
4
|
Chen YC, Chu CM, Yeh CT and Liaw YF:
Natural course following the onset of cirrhosis in patients with
chronic Hepatitis B: A long-term follow-up study. Hepatol Int.
1:267–273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chu CM and Liaw YF: Hepatitis B
virus-related cirrhosis: Natural history and treatment. Semin Liver
Dis. 26:142–152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bataller R and Brenner DA: Liver fibrosis.
J Clin Invest. 115:209–218. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pinzani M: Liver fibrosis. Springer Semin
Immunopathol. 21:475–490. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Safadi R and Friedman SL: Hepatic
fibrosis-role of hepatic stellate cell activation. MedGenMed.
4:272002.PubMed/NCBI
|
|
9
|
Trepo C, Chan HL and Lok A: Hepatitis B
virus infection. Lancet. 384:2053–2063. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sun M and Kisseleva T: Reversibility of
liver fibrosis. Clin Res Hepatol Gastroenterol. 39 (Suppl
1):S60–S63. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calvaruso V and Craxi A: Regression of
fibrosis after HBV antiviral therapy. Is cirrhosis reversible?
Liver Int. 34 (Suppl 1):S85–S90. 2014. View Article : Google Scholar
|
|
12
|
Jiang XI, Luo Y, Zhao S, Chen Q, Jiang C,
Dai Y, Chen Y and Cao Z: Clinical significance and expression of
microRNA in diabetic patients with erectile dysfunction. Exp Ther
Med. 10:213–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jia W, Wu Y, Zhang Q, Gao GE, Zhang C and
Xiang Y: Expression profile of circulating microRNAs as a promising
fingerprint for cervical cancer diagnosis and monitoring. Mol Clin
Oncol. 3:851–858. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Graziano A, Lo Monte G, Piva I, Caserta D,
Karner M, Engl B and Marci R: Diagnostic findings in adenomyosis: A
pictorial review on the major concerns. Eur Rev Med Pharmacol Sci.
19:1146–1154. 2015.PubMed/NCBI
|
|
15
|
Hayes CN and Chayama K: MicroRNAs as
biomarkers for liver disease and hepatocellular carcinoma. Int J
Mol Sci. 17:2802016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ichikawa Y, Joshita S, Umemura T,
Shobugawa Y, Usami Y, Shibata S, Yamazaki T, Fujimori N, Komatsu M,
Matsumoto A and Tanaka E: Serum Wisteria floribunda
agglutinin-positive human Mac-2 binding protein may predict liver
fibrosis and progression to hepatocellular carcinoma in patients
with chronic hepatitis B virus infection. Hepatol Res. 47:226–233.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu Y, Cheng LS, Wu SD, Wang SQ, Li L, She
WM, Li J, Wang JY and Jiang W: IL-10-producing regulatory B-cells
suppressed effector T-cells but enhanced regulatory T-cells in
chronic HBV infection. Clin Sci (Lond). 130:907–919. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
MacParland SA, Ma XZ, Chen L, Khattar R,
Cherepanov V, Selzner M, Feld JJ, Selzner N and McGilvray ID:
Lipopolysaccharide and tumor necrosis factor alpha inhibit
interferon signaling in hepatocytes by increasing ubiquitin-like
protease 18 (USP18) expression. J Virol. 90:5549–5560. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chang TS, Chen CL, Wu YC, Liu JJ, Kuo YC,
Lee KF, Lin SY, Lin SE, Tung SY, Kuo LM, et al: Inflammation
promotes expression of stemness-related properties in HBV-related
hepatocellular carcinoma. PLoS One. 11:e01498972016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Li C, Deng M, Hu J, Li X, Chen L, Ju Y,
Hao J and Meng S: Chronic inflammation contributes to the
development of hepatocellular carcinoma by decreasing miR-122
levels. Oncotarget. 7:17021–17034. 2016.PubMed/NCBI
|
|
21
|
Chang L, Lan T, Wu L, Li C, Yuan Y and Liu
Z: The association between three IL-6 polymorphisms and HBV-related
liver diseases: A meta-analysis. Int J Clin Exp Med. 8:17036–17045.
2015.PubMed/NCBI
|
|
22
|
Lan T, Chang L, Wu L and Yuan YF: IL-6
plays a crucial role in HBV infection. J Clin Transl Hepatol.
3:271–276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chinese Society of Hepatology, Chinese
Medical Association: Chinese Society of Infectious Diseases,
Chinese Medical Association, . The guidelines of prevention and
treatment for chronic Hepatitis B. Zhonghua Gan Zang Bing Za Zhi.
13:881–891. 2005.(In Chinese). PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Badding MA, Schwegler-Berry D, Park JH,
Fix NR, Cummings KJ and Leonard SS: Sintered indium-tin oxide
particles induce pro-inflammatory responses in vitro, in part
through inflammasome activation. PLoS One. 10:e01243682015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hunter CA and Jones SA: IL-6 as a keystone
cytokine in health and disease. Nat Immunol. 16:448–457. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanaka T, Narazaki M and Kishimoto T: IL-6
in inflammation, immunity, and disease. Cold Spring Harb Perspect
Biol. 6:a0162952014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Baeuerle PA and Henkel T: Function and
activation of NF-kappa B in the immune system. Annu Rev Immunol.
12:141–179. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tone M, Powell MJ, Tone Y, Thompson SA and
Waldmann H: IL-10 gene expression is controlled by the
transcription factors Sp1 and Sp3. J Immunol. 165:286–291. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yao X, Huang J, Zhong H, Shen N, Faggioni
R, Fung M and Yao Y: Targeting interleukin-6 in inflammatory
autoimmune diseases and cancers. Pharmacol Ther. 141:125–139. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Luo Q, Ma X, Wahl SM, Bieker JJ, Crossley
M and Montaner LJ: Activation and repression of interleukin-12 p40
transcription by erythroid Kruppel-like factor in macrophages. J
Biol Chem. 279:18451–18456. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Aarstad HH, Vintermyr OK, Ulvestad E,
Kross K, Heimdal JH and Aarstad HJ: In vitro-stimulated IL-6
monocyte secretion and in vivo peripheral blood T lymphocyte
activation uniquely predicted 15-year survival in patients with
head and neck squamous cell carcinoma. PLoS One. 10:e01297242015.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Varshney J and Subramanian S: MicroRNAs as
potential target in human bone and soft tissue sarcoma
therapeutics. Front Mol Biosci. 2:312015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liz J and Esteller M: lncRNAs and
microRNAs with a role in cancer development. Biochim Biophys Acta.
1859:169–176. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Pauley KM, Satoh M, Chan AL, Bubb MR,
Reeves WH and Chan EK: Upregulated miR-146a expression in
peripheral blood mononuclear cells from rheumatoid arthritis
patients. Arthritis Res Ther. 10:R1012008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abou-Zeid A, Saad M and Soliman E:
MicroRNA 146a expression in rheumatoid arthritis: Association with
tumor necrosis factor-alpha and disease activity. Genet Test Mol
Biomarkers. 15:807–812. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamasaki K, Nakasa T, Miyaki S, Yamasaki
T, Yasunaga Y and Ochi M: Angiogenic microRNA-210 is present in
cells surrounding osteonecrosis. J Orthop Res. 30:1263–1270. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li X, Gibson G, Kim JS, Kroin J, Xu S, van
Wijnen AJ and Im HJ: MicroRNA-146a is linked to pain-related
pathophysiology of osteoarthritis. Gene. 480:34–41. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Li X, Kroin JS, Kc R, Gibson G, Chen D,
Corbett GT, Pahan K, Fayyaz S, Kim JS, van Wijnen AJ, et al:
Altered spinal microRNA-146a and the microRNA-183 cluster
contribute to osteoarthritic pain in knee joints. J Bone Miner Res.
28:2512–2522. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Curtale G, Citarella F, Carissimi C,
Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V
and Macino G: An emerging player in the adaptive immune response:
MicroRNA-146a is a modulator of IL-2 expression and
activation-induced cell death in T lymphocytes. Blood. 115:265–273.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Taganov KD, Boldin MP, Chang KJ and
Baltimore D: NF-kappaB-dependent induction of microRNA miR-146, an
inhibitor targeted to signaling proteins of innate immune
responses. Proc Natl Acad Sci USA. 103:12481–12486. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Larner-Svensson HM, Williams AE, Tsitsiou
E, Perry MM, Jiang X, Chung KF and Lindsay MA: Pharmacological
studies of the mechanism and function of interleukin-1beta-induced
miRNA-146a expression in primary human airway smooth muscle. Respir
Res. 11:682010. View Article : Google Scholar : PubMed/NCBI
|
